University of Cambridge > > Electrical Engineering > Urological cancer detection and technology innovation: opportunities and challenges.

Urological cancer detection and technology innovation: opportunities and challenges.

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact Kirsty Shepherd.

Vincent Gnanapragasam is Professor of Urology in the University of Cambridge and an Honorary Consultant Urologist at Addenbrooke’s Hospital, Cambridge. Vincent’s research has covered the full spectrum of basic science, translational, clinical and epidemiological disciplines in prostate cancer. He has developed and implemented novel prognostic prediction models for both group stratified cohorts Cambridge Prognostic Groups and for individualised prediction Predict Prostate for personalised management of prostate cancer. In 2021 the Cambridge Prognostic Groups was officially adopted by the UK National Institute for Health and Care l Excellence (NICE) as the new recommended risk stratification tool in the national prostate cancer guidelines (NG131).Predict prostate is the only decision aid endorsed by the UK NICE National Guidelines on prostate cancer. He has also pioneered risk stratified pathways for active surveillance follow up and setup one of the first dedicated surveillance clinics for early disease monitoring. He has developed and led numerous investigator led multicentre clinical trials including TAPS01 , Predict Prostate RCT , PRIM biomarker study, and the NIH Ri4i funded CAMPROBE study (based on his own invention of a new simple device for infection free prostate biopsies). To further interdisciplinary research in prostate cancer he established the Translational Prostate Cancer Group (TPCG) in Cambridge with colleagues from urology, oncology, radiology, pathology and basic science. He has also established links with STEM scientists to develop biosensors for cancer detection across different platforms. He is also Chief Investigator of the DIAMOND study which hold over 3000 bio-samples, tissue and annotated clinical data for biomarker discovery in urological diseases. More recently, with colleagues from the TPCG , he has established a platform for integrated genomics and clinical profiling to explore the potential for targeted adjuvant therapies to improve primary cure rates in poor prognosis prostate cancer. In the University of Cambridge, he leads the Division of Urology in the Department of Surgery and established the Cambridge Urology Translational Research and Clinical Trials office which has to date recruited>1600 patients to various NIHR and portfolio urology trials. He is clinical directorate lead for urology research. He holds patents, editorial positions and has won prizes for research, including the CE Alken prize, Urological Research Society Medal and a Hunterian Professorship. In the University of Cambridge, he is a recipient of the Vice-Chancellors Award for Research Impact (Established Researcher).

This talk is part of the Electrical Engineering series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.


© 2006-2024, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity